The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Smarter Regulation Can Help Cut Drug Prices, Says EU Agency Head

Smarter Regulation Can Help Cut Drug Prices, Says EU Agency Head

December 10, 2015 • By Ben Hirschler

  • Tweet
  • Email
Print-Friendly Version / Save PDF

LONDON (Reuters)—Europe’s top drug regulator weighed into the medicine pricing debate on Wednesday, arguing a smarter and faster pharmaceutical approval system was needed to help rein in the spiraling cost of new treatments.

You Might Also Like
  • France Gets G7 to Discuss Global Regulation of Medicine Prices
  • Europe Launches New Fast Approval Scheme for Promising Drugs
  • Americans Want Medicare to Help Negotiate Down Drug Prices

In exchange for speeding up the approval process, society would expect manufacturers to charge less for innovative medicines, European Medicines Agency (EMA) Executive Director Guido Rasi says.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Companies are under fire over pricing on both sides of the Atlantic, with Europe’s state-backed health systems struggling to afford costly new therapies, while U.S. presidential candidate Hillary Clinton has pledged action on the issue.

Although the job of the EMA—Europe’s equivalent of the U.S. Food and Drug Administration—is simply to ensure drugs are safe, effective and of good quality, Rasi believes the watchdog can also make an important contribution on the cost side.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

“As regulators, we want to recommend innovative medicines for approval that are affordable. That is why we are fostering a better model for the development of medicines,” he told reporters in a briefing.

Central to this is the EMA’s so-called “adaptive pathways” initiative, under which drugs would be approved early for restricted patient populations based on small initial clinical trials.

Approval would then be expanded progressively, based on additional studies, reflecting the reality that evidence develops continually as clinical data builds up. As with the existing regulatory system, a medicine could be pulled from the market if new data revealed unexpected problems.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Rasi says this approach would be “leaner and more efficient” and, importantly, should help bring down the cost of developing new drugs.

“Our expectation is that companies will reflect this by reducing the price of medicines for the benefit of patients and for the sustainability of our healthcare systems,” he says.

The new adaptive licensing system could reduce “by years” the time taken to win approval for a new medicine and should be applicable in future to many, although not all, new medicines, Rasi adds.

Advances in medical science mean the world has seen a bumper haul of expensive new medicines approved for use in the past two years. Treatments for cancer, in particular, often cost around $10,000 a month in the U. S., although they are typically cheaper in Europe.

A rapid pace of drug launches is expected to continue in the years ahead, with 225 new drugs forecast to be approved between 2016 and 2020, according to a report from industry data firm IMS Health last month.

Pages: 1 2 | Single Page

Filed Under: Drug Updates, Pharma Co. News Tagged With: costs, Drugs, Europe, European Medicines Agency

You Might Also Like:
  • France Gets G7 to Discuss Global Regulation of Medicine Prices
  • Europe Launches New Fast Approval Scheme for Promising Drugs
  • Americans Want Medicare to Help Negotiate Down Drug Prices
  • EMA Flags Faulty Generic Drug Data, Backs Sales Halt

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)